Psychometrics and applications of a novel self-report measure of emicizumab adherence: VERITASNexGen.

Amanda I Okolo Amy D ShapiroIsaac JansonJames OkungadeChris RobersonMacKenzie NolteLisa LittnerWilliam Kronenberger

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2023)

The VERITASNexGen is the first validated multifactorial patient-report measure of adherence designed specifically for emicizumab treatment. Results suggest excellent adherence, with only 4%-13% of participants reporting suboptimal adherence to different components of the treatment regimen. Used in conjunction with other adherence measures, VERITAS-NexGen meets a crucial need for monitoring and understanding patient adherence to emicizumab in clinical and research settings.

Keyphrases

glycemic control
case report
type diabetes
emergency department
metabolic syndrome
combination therapy
smoking cessation